The World’s First Autonomous Blood Drawing Device

Project Information

VD-1

Grant agreement ID: 190176843

DOI

10.3030/190176843

Project closed

EC signature date 14 July 2023

Start date 1 June 2023

End date 28 February 2025

Funded under

• The European Innovation Council (EIC)

Total cost

€ 2 975 301,25

EU contribution

€ 2 082 710,88

Coordinated by

VITESTRO BV
Netherlands

Periodic Reporting for period 2 - VD-1 (The World’s First Autonomous Blood Drawing Device)

Reporting period: 2024-04-01 to 2025-02-28

Summary of the context and overall objectives of the project

Vitestro has created the first fully-autonomous device that draws blood from patients. Our solution, called VD-1, performs the whole
venipuncture procedure, from vein detection to bandage application, without any human intervention. We have fully developed our
technology in-house and protected it with seven patents. More than 2,500 patients have tried our solution: the user acceptance, first-time
success rate, and hemolysis rate are comparable to those measured using human nurses. The VD-1 will mitigate the chronic shortage
of healthcare personnel. It will also standardize the venipuncture process, which has been substantially unchanged for decades. We target
two categories of customers – lab chains and hospital labs – and we have launching customers in both of them. Vitestro has a team of
over 70 people, including technical, medical, regulatory, and commercial expertise.

Work performed from the beginning of the project to the end of the period covered by the report and main results achieved so far

- We worked on the A.D.O.P.T. Trial, which is the largest trial in autonomous blood drawing worldwide.
- We enrolled the first 1,400 patients in 4 European Hospital Laboratory sites.
- We have completed the technology objectives, increase safety and performance and preparing the device for industrialization.
- We have solved multiple technical challenges in integration of hardware and software.
- We have obtained CE marking and can thereby sell the device within the EU.
- We have placed the first two devices in a commercial setting in the OLVG hospital in Amsterdam

Progress beyond the state of the art and expected potential impact (including the socio-economic impact and the wider societal implications of the project so far)

- We have raised a Series A-1 funding round of €20M with a consortium of multiple EU and U.S. partners, including EIC Fund
- We have presented trial results at Dutch congress NVKC as well as NVML
- We have signed contracts with 5 different customers for a total of 13 devices
- We have grown the team from 50 to ~100 people
- We have participated as a semi-finalist in the ADLM Disruptive Innovation Award
- We have a total of nine patents filed on all essential parts of the device